Fate Therapeutics Announces Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Lupus Erythematosus (SLE) at the CCR
Fate Therapeutics announced clinical safety, efficacy, and translational data for its off-the-shelf CAR T-cell product candidate, FT819, in treating systemic lupus erythematosus (SLE). The Phase 1 study data demonstrated clinically meaningful and durable improvements in disease activity and patient-reported outcomes following a single dose combined…